Buscar
Mostrando ítems 1-10 de 151
An integrated meta-analysis of secretome and proteome identify potential biomarkers of pancreatic ductal adenocarcinoma
(2020-03-01)
Pancreatic ductal adenocarcinoma (PDAC) is extremely aggressive, has an unfavorable prognosis, and there are no biomarkers for early detection of the disease or identification of individuals at high risk for morbidity or ...
Multidrug transporter MRP4/ABCC4 as a key determinant of pancreatic cancer aggressiveness
(Nature, 2020-08)
Recent findings show that MRP4 is critical for pancreatic ductal adenocarcinoma (PDAC) cell proliferation. Nevertheless, the significance of MRP4 protein levels and function in PDAC progression is still unclear. The aim ...
MicroRNA modulated networks of adaptive and innate immune response in pancreatic ductal adenocarcinoma
(2019-05-01)
Despite progress in treatment strategies, only ~24% of pancreatic ductal adenocarcinoma (PDAC) patients survive >1 year. Our goal was to elucidate deregulated pathways modulated by microRNAs (miRNAs) in PDAC and Vater ...
Relatório de viagem ao exterior: Toronto, Canadá
(CPRM, 2022)
Relatório de viagem ao exterior: Toronto, Canadá
(CPRM, 2022)
Relatório de viagem ao Canadá: março de 2007
(CPRM, 2017)
Relatório de viagem ao exterior: Toronto, Canadá
(CPRM, 2022)
MicroRNoma do carcinoma de pâncreas
(Universidade Estadual Paulista (UNESP), 2016)